| scholarly article | Q13442814 |
| P356 | DOI | 10.1182/BLOOD-2005-10-4066 |
| P698 | PubMed publication ID | 16249375 |
| P2093 | author name string | C Glenn Begley | |
| Moonkyoung Um | |||
| Angus M Sinclair | |||
| Chris Spahr | |||
| Leigh Busse | |||
| Gwyneth Van | |||
| Michael B Bass | |||
| Steve Elliott | |||
| Ildiko Sarosi | |||
| Hsieng Lu | |||
| P433 | issue | 5 | |
| P304 | page(s) | 1892-1895 | |
| P577 | publication date | 2005-10-25 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Anti-Epo receptor antibodies do not predict Epo receptor expression | |
| P478 | volume | 107 |
| Q48525773 | A premature obituary for erythropoietin analogues |
| Q37021210 | Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial |
| Q49375977 | Alternative Erythropoietin Receptors in the Nervous System |
| Q35586330 | Analysis of HIF-1a and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications |
| Q35933820 | Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA. |
| Q34068226 | Association Between Pharmaceutical Support and Basic Science Research on Erythropoiesis-Stimulating Agents |
| Q39990843 | Bad Science: Cause and Consequence |
| Q46888439 | Blunting effect of hypoxia on the proliferation and differentiation of human primary and rat L6 myoblasts is not counteracted by Epo. |
| Q35768736 | Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia |
| Q38126361 | Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents |
| Q36494595 | Darbepoetin alfa: a review of its use in the treatment of anaemia in patients with cancer receiving chemotherapy |
| Q41892226 | Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia |
| Q37686245 | Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact |
| Q36526182 | Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. |
| Q37072564 | Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? |
| Q28732847 | Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles |
| Q82573739 | EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment |
| Q37727882 | EPO-receptor is present in mouse C2C12 and human primary skeletal muscle cells but EPO does not influence myogenesis |
| Q90637405 | Effect of fetal bovine serum on erythropoietin receptor expression and viability of breast cancer cells |
| Q49541601 | Effects of Erythropoietin Receptor Activity on Angiogenesis, Tubular Injury and Fibrosis in Acute Kidney Injury: A "U-Shaped" Relationship. |
| Q35858979 | Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. |
| Q34826770 | Epo receptors are not detectable in primary human tumor tissue samples |
| Q30908819 | Erythropoetin receptor expression in the human diabetic retina |
| Q36246631 | Erythropoiesis stimulating agents and reno-protection: a meta-analysis |
| Q37827440 | Erythropoiesis, anemia and the bone marrow microenvironment. |
| Q33630871 | Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes |
| Q37098040 | Erythropoietic agents and the elderly |
| Q86893314 | Erythropoietin |
| Q89864223 | Erythropoietin Receptor Signaling Supports Retinal Function after Vascular Injury |
| Q48120672 | Erythropoietin Signaling Increases Choroidal Macrophages and Cytokine Expression, and Exacerbates Choroidal Neovascularization. |
| Q89587288 | Erythropoietin Signaling in the Microenvironment of Tumors and Healthy Tissues |
| Q33761779 | Erythropoietin and the effect of oxygen during proliferation and differentiation of human neural progenitor cells. |
| Q48312143 | Erythropoietin as Additive of HTK Preservation Solution in Cold Ischemia/Reperfusion Injury of Steatotic Livers |
| Q36404124 | Erythropoietin deficiency decreases vascular stability in mice. |
| Q28583929 | Erythropoietin enhances immunostimulatory properties of immature dendritic cells |
| Q37852282 | Erythropoietin for oncology supportive care |
| Q47806649 | Erythropoietin in diabetic retinopathy. |
| Q35574024 | Erythropoietin in the intensive care unit: beyond treatment of anemia |
| Q24240202 | Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data |
| Q24242864 | Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data |
| Q47143849 | Erythropoietin promoted the proliferation of hepatocellular carcinoma through hypoxia induced translocation of its specific receptor |
| Q36840259 | Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis |
| Q35025478 | Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma |
| Q28573061 | Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span |
| Q34235219 | Erythropoietin receptor signaling is membrane raft dependent |
| Q38292589 | Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells |
| Q36943310 | Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations |
| Q34024987 | Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial |
| Q83540155 | Evaluating surface erythropoietin receptor in multiple myeloma |
| Q34182011 | Evaluation of functional erythropoietin receptor status in skeletal muscle in vivo: acute and prolonged studies in healthy human subjects |
| Q36854821 | Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients |
| Q36091444 | Expression of platelet-derived growth factor BB, erythropoietin and erythropoietin receptor in canine and feline osteosarcoma. |
| Q35217404 | Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues |
| Q36682779 | Functional significance of erythropoietin receptor on tumor cells |
| Q28587709 | Gata4 and Sp1 regulate expression of the erythropoietin receptor in cardiomyocytes |
| Q92223527 | Impact of Inadequate Methods and Data Analysis on Reproducibility |
| Q42879369 | Impaired ventilatory acclimatization to hypoxia in female mice overexpressing erythropoietin: unexpected deleterious effect of estradiol in carotid bodies |
| Q37210445 | Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells |
| Q37252771 | Managing anemia in lymphoma and multiple myeloma |
| Q35786598 | Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells |
| Q33433206 | No evidence for protective erythropoietin alpha signalling in rat hepatocytes |
| Q26866945 | Physiology and pharmacology of erythropoietin |
| Q80539477 | Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion |
| Q33988762 | Prognostic significance of erythropoietin in pancreatic adenocarcinoma |
| Q37471768 | Progress in detecting cell-surface protein receptors: the erythropoietin receptor example |
| Q34504572 | Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? |
| Q33878270 | Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors |
| Q37807314 | Randomized Controlled Trials of the Erythroid-Stimulating Agents in Cancer Patients |
| Q48616675 | Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents |
| Q34107767 | Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro |
| Q33654147 | Retracted: EPO Receptor Gain-of-Function Causes Hereditary Polycythemia, Alters CD34+ Cell Differentiation and Increases Circulating Endothelial Precursors |
| Q35164312 | Risks of Venous Thromboembolism and Mortality Associated With Erythropoiesis-Stimulating Agents for the Treatment of Cancer-Associated Anemia. |
| Q84080832 | Role of erythropoietin receptor expression in malignant melanoma |
| Q34326017 | Role of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia |
| Q99405262 | Role of the erythropoietin receptor in Lung Cancer cells: erythropoietin exhibits angiogenic potential |
| Q35587285 | Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin |
| Q48184678 | Should we ignore western blots when selecting antibodies for other applications? |
| Q35817949 | Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO |
| Q33379554 | Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy |
| Q80479295 | Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care |
| Q38595266 | Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis |
| Q38676449 | The ABCs of finding a good antibody: How to find a good antibody, validate it, and publish meaningful data |
| Q34291437 | The effect of erythropoietin on normal and neoplastic cells |
| Q91668875 | The endogenous erythropoietin in correlation with other erythrocytic parameters in patients with head and neck squamous cell carcinoma treated with platinum-based induction chemotherapy |
| Q28565261 | The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection |
| Q37639378 | The erythropoietin receptor is not required for the development, function, and aging of rods and cells in the retinal periphery |
| Q39347324 | The osteogenic effect of erythropoietin on human mesenchymal stromal cells is dose-dependent and involves non-hematopoietic receptors and multiple intracellular signaling pathways |
| Q38123160 | The role and regulation of erythropoietin (EPO) and its receptor in skeletal muscle: how much do we really know? |
| Q45792614 | Tissue protection by erythropoietin: new findings in a moving field |
| Q38176752 | Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer |
| Q42921510 | Up‐regulation of erythropoietin receptor by nitric oxide mediates hypoxia preconditioning |
| Q36758037 | Widespread expression of erythropoietin receptor in brain and its induction by injury |
Search more.